Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma

Hatem M Marey, Amin F EllakwaDepartment of Ophthalmology, Faculty of Medicine, Menoufiya University, Shibin el Kom, EgyptPurpose: To demonstrate the role of intravitreal bevacizumab in regression of iris neovascularization, and intraocular pressure (IOP) control in neovascular glaucoma.Methods: A re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marey HM, Ellakwa AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/28e17fb3e26942e3abea696e5ba5f9b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28e17fb3e26942e3abea696e5ba5f9b9
record_format	dspace
spelling	oai:doaj.org-article:28e17fb3e26942e3abea696e5ba5f9b92021-12-02T07:44:05ZIntravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma1177-54671177-5483https://doaj.org/article/28e17fb3e26942e3abea696e5ba5f9b92011-06-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-with-or-without-mitomycin-c-trabeculectomy-in-a7712https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Hatem M Marey, Amin F EllakwaDepartment of Ophthalmology, Faculty of Medicine, Menoufiya University, Shibin el Kom, EgyptPurpose: To demonstrate the role of intravitreal bevacizumab in regression of iris neovascularization, and intraocular pressure (IOP) control in neovascular glaucoma.Methods: A retrospective random case series study was performed. Twenty eyes of 20 patients who presented with neovascular glaucoma were treated with intravitreal bevacizumab 2.5 mg in 0.1 mL. Retinal photocoagulation was performed for all cases as soon as possible after intravitreal injection and subscleral trabeculectomy with mitomycin C 0.4 mg/mL for 3 minutes for cases having peripheral anterior synechiae. Cases were followed up for 12 months when regression of iris neovessels, IOP control, improvement in visual acuity, and success of filtering surgery were recorded.Results: All cases showed complete regression of iris neovessels at 2 months after injection; recurrence of iris neovessels was observed in 4 cases (20%) at 4 months and in 14 cases (70%) at 8 months follow-up. The mean IOP dropped from 41.45 &plusmn; 5.89 mmHg preoperatively, to 19.3 &plusmn; 5.5 mmHg and 17.75 &plusmn; 3.74 mmHg at 6 months and 12 months postoperatively, respectively. The success rate of subscleral trabeculectomy with mitomycin C after intravitreal bevacizumab was 77.8%. Visual acuity was improved in 17 cases (85%) from preoperative 0.12 &plusmn; 0.11 to 0.26 &plusmn; 0.2 postoperative.Conclusion: Intravitreal bevacizumab has a role in regression of iris neovessels and IOP control in neovascular glaucoma cases and also in increasing the success rate of subscleral trabeculectomy with mitomycin C; however this role has a limited time and reinjection is needed to maintain this effect.Keywords: bevacizumab, intravitreal injection, mitomycin C, neovascular glaucoma, subscleral trabeculectomyMarey HMEllakwa AFDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 841-845 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Marey HM Ellakwa AF Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
description	Hatem M Marey, Amin F EllakwaDepartment of Ophthalmology, Faculty of Medicine, Menoufiya University, Shibin el Kom, EgyptPurpose: To demonstrate the role of intravitreal bevacizumab in regression of iris neovascularization, and intraocular pressure (IOP) control in neovascular glaucoma.Methods: A retrospective random case series study was performed. Twenty eyes of 20 patients who presented with neovascular glaucoma were treated with intravitreal bevacizumab 2.5 mg in 0.1 mL. Retinal photocoagulation was performed for all cases as soon as possible after intravitreal injection and subscleral trabeculectomy with mitomycin C 0.4 mg/mL for 3 minutes for cases having peripheral anterior synechiae. Cases were followed up for 12 months when regression of iris neovessels, IOP control, improvement in visual acuity, and success of filtering surgery were recorded.Results: All cases showed complete regression of iris neovessels at 2 months after injection; recurrence of iris neovessels was observed in 4 cases (20%) at 4 months and in 14 cases (70%) at 8 months follow-up. The mean IOP dropped from 41.45 &plusmn; 5.89 mmHg preoperatively, to 19.3 &plusmn; 5.5 mmHg and 17.75 &plusmn; 3.74 mmHg at 6 months and 12 months postoperatively, respectively. The success rate of subscleral trabeculectomy with mitomycin C after intravitreal bevacizumab was 77.8%. Visual acuity was improved in 17 cases (85%) from preoperative 0.12 &plusmn; 0.11 to 0.26 &plusmn; 0.2 postoperative.Conclusion: Intravitreal bevacizumab has a role in regression of iris neovessels and IOP control in neovascular glaucoma cases and also in increasing the success rate of subscleral trabeculectomy with mitomycin C; however this role has a limited time and reinjection is needed to maintain this effect.Keywords: bevacizumab, intravitreal injection, mitomycin C, neovascular glaucoma, subscleral trabeculectomy
format	article
author	Marey HM Ellakwa AF
author_facet	Marey HM Ellakwa AF
author_sort	Marey HM
title	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
title_short	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
title_full	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
title_fullStr	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
title_full_unstemmed	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
title_sort	intravitreal bevacizumab with or without mitomycin c trabeculectomy in the treatment of neovascular glaucoma
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/28e17fb3e26942e3abea696e5ba5f9b9
work_keys_str_mv	AT mareyhm intravitrealbevacizumabwithorwithoutmitomycinctrabeculectomyinthetreatmentofneovascularglaucoma AT ellakwaaf intravitrealbevacizumabwithorwithoutmitomycinctrabeculectomyinthetreatmentofneovascularglaucoma
_version_	1718399208625537024

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma

Ejemplares similares